Literature DB >> 15302892

Hepatobiliary disposition of the metabolically stable opioid peptide [D-Pen2, D-Pen5]-enkephalin (DPDPE): pharmacokinetic consequences of the interplay between multiple transport systems.

Keith A Hoffmaster1, Maciej J Zamek-Gliszczynski, Gary M Pollack, Kim L R Brouwer.   

Abstract

[D-Pen2,D-Pen5]-Enkephalin (DPDPE) is excreted extensively into the bile. Although DPDPE is transported by P-glycoprotein (P-gp), multidrug resistance-associated protein 2 (Mrp2) has been identified as an important mechanism for DPDPE transport across the canalicular membrane of the hepatocyte. The present studies determined the relative impact of Mrp2 and P-gp on the hepatobiliary disposition of [3H]DPDPE in isolated perfused rat livers (IPLs). Perfusate clearance of [3H]DPDPE was not different between livers from control and Mrp2-deficient (TR-) rats. Biliary excretion of [3H]DPDPE in IPLs from Wistar control rats was rapid and extensive. However, when [3H]DPDPE was administered to livers from TR- rats, the rate and extent of excretion decreased significantly. Surprisingly, in the presence of the P-gp inhibitor GF120918 [N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide], biliary excretion of [3H]DPDPE was not inhibited in control livers. In contrast, administration of GF120918 to TR- livers further reduced the maximal excretion rate and decreased net biliary excretion of [3H]DPDPE by 87%. GF120918 administration caused an unexpected increase in perfusate clearance in both control and TR- rat livers. At distribution equilibrium, [3H]DPDPE liver/perfusate partitioning was higher in GF120918-treated livers. Results of pharmacokinetic modeling were consistent with the hypothesis that GF120918 inhibited a [3H]DPDPE basolateral excretion mechanism. Mrp2 is the primary mechanism for [3H]DPDPE biliary excretion, and P-gp facilitates excretion of [3H]DPDPE only in the absence of functional Mrp2. [3H]DPDPE is a substrate for a basolateral efflux mechanism that is sensitive to inhibition by GF120918. These data emphasize the importance of using appropriate model systems and comprehensive pharmacokinetic modeling in elucidating the complex interplay between multiple transport systems.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15302892     DOI: 10.1124/jpet.104.070201

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  Hepatobiliary disposition of 3alpha,6alpha,7alpha,12alpha-tetrahydroxy-cholanoyl taurine: a substrate for multiple canalicular transporters.

Authors:  Vandana Megaraj; Takashi Iida; Paiboon Jungsuwadee; Alan F Hofmann; Mary Vore
Journal:  Drug Metab Dispos       Date:  2010-07-19       Impact factor: 3.922

Review 2.  Transport systems for opioid peptides in mammalian tissues.

Authors:  Vadivel Ganapathy; Seiji Miyauchi
Journal:  AAPS J       Date:  2005-12-29       Impact factor: 4.009

3.  Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding.

Authors:  Souzan B Yanni; P Brian Smith; Daniel K Benjamin; Patrick F Augustijns; Dhiren R Thakker; Pieter P Annaert
Journal:  Biopharm Drug Dispos       Date:  2011-03-30       Impact factor: 1.627

4.  Decreased hepatic breast cancer resistance protein expression and function in multidrug resistance-associated protein 2-deficient (TR⁻) rats.

Authors:  Wei Yue; Jin Kyung Lee; Koji Abe; Yuichi Sugiyama; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2010-11-24       Impact factor: 3.922

5.  In vitro investigation of the hepatobiliary disposition mechanisms of the antifungal agent micafungin in humans and rats.

Authors:  Souzan B Yanni; Patrick F Augustijns; Daniel K Benjamin; Kim L R Brouwer; Dhiren R Thakker; Pieter P Annaert
Journal:  Drug Metab Dispos       Date:  2010-07-06       Impact factor: 3.922

Review 6.  Methods to evaluate biliary excretion of drugs in humans: an updated review.

Authors:  Giulia Ghibellini; Elaine M Leslie; Kim L R Brouwer
Journal:  Mol Pharm       Date:  2006 May-Jun       Impact factor: 4.939

7.  Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice.

Authors:  Xianbin Tian; Jun Li; Maciej J Zamek-Gliszczynski; Arlene S Bridges; Peijin Zhang; Nita J Patel; Thomas J Raub; Gary M Pollack; Kim L R Brouwer
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

8.  Evaluation of the P-glycoprotein (Abcb1) affinity status of a series of morphine analogs: comparative study with meperidine analogs to identify opioids with minimal P-glycoprotein interactions.

Authors:  Hazem E Hassan; Susan L Mercer; Christopher W Cunningham; Andrew Coop; Natalie D Eddington
Journal:  Int J Pharm       Date:  2009-04-05       Impact factor: 5.875

9.  Apparent differences in mechanisms of harmol sulfate biliary excretion in mice and rats.

Authors:  Maciej J Zamek-Gliszczynski; Keith A Hoffmaster; Ken-ichi Nezasa; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2008-08-21       Impact factor: 3.922

10.  Hepatobiliary disposition of troglitazone and metabolites in rat and human sandwich-cultured hepatocytes: use of Monte Carlo simulations to assess the impact of changes in biliary excretion on troglitazone sulfate accumulation.

Authors:  Jin Kyung Lee; Tracy L Marion; Koji Abe; Changwon Lim; Gary M Pollock; Kim L R Brouwer
Journal:  J Pharmacol Exp Ther       Date:  2009-10-02       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.